|
Fred Volinsky began his career as an Emergency Physician where he spent 8 years on the attending staff of Massachusetts General Hospital (MGH) and Brigham and Women's Hospital in Boston. He was one of the original faculty members of the Harvard Residency in Emergency Medicine and the Harvard Department of Emergency Medicine at MGH. While at Harvard, Volinsky developed a medical device that he licensed to Moser Medical. Dr. Volinsky continued to follow his entrepreneurial interests and co-founded Exhale Pharmaceuticals, now known as CoTherix (CTRX-Nasdaq). He left MGH in 2000 to become Managing Director of RCT BioVentures, an early stage life science fund where he was an investor in a variety of biotechnology companies including Cylene Pharmaceuticals, Catalyst BioSciences, Kerberos Proximal Solutions, Imagine Pharmaceuticals, and Arizeke Pharmaceuticals. He has held Directorships at Myometrix, Cylene Pharmaceuticals, Imagine Pharmaceuticals, Kerberos Proximal Solutions, and Catalyst Biosciences. Dr. Volinsky is a Co-Chairman of the Stanford BioBootcamp and the founder and Co-Chairman of the UCSD BioBootcamp. He is a member of the Advisory Board of the UCSD Cancer Center, the Scientific Advisory Board to the Bailard Life Science Fund, and the Clinical Advisory Board of Catalyst Biosciences. Volinsky is also a consultant to Threshold Pharmaceuticals and Diobex. Dr. Volinsky earned his medical degree at Eastern Virginia Medical School. He completed a residency in Emergency Medicine at Madigan Army Medical center and was elected as a Fellow to the American College of Emergency Physicians. Volinsky spent 6 years as a military physician and was an attending physician at Walter Reed Army Center. | 